FUSION PHARMACEUTICALS INC (FUSN) Stock News
NASDAQ:FUSN - Nasdaq - CA36118A1003 - Common Stock - Currency: USD
FUSN Latest News, Press Relases and Analysis
Acquisition of Fusion Pharmaceuticals Completed
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs),...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fusion Pharmaceuticals (NASDAQ:FUSN) just reported results for the fourth quart...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, X
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
